Published in Cancer Weekly, November 25th, 1996
The seminar was sponsored through an educational grant from Myriad Genetic Laboratories, Inc., which offers BRACAnalysis - comprehensive BRCA1 and BRCA2 sequence analysis for susceptibility to breast and ovarian cancers. BRCA1 and BRCA2 gene mutations are responsible for about 90 percent of all hereditary ovarian and early-onset breast cancers.
Jean Jenkins, R.N., M.S.N., National Center for Human Genome Research, summed up the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.